Protocol No.: 20240178

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
Principal Investigator
Almubarak, Mohammed
Phase
III
Age Group
Adult
Applicable Disease Site
Lung Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066

View on ClinicalTrials.gov